A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
INDICATION:
Metastatic bone sarcomas: conventional high grade osteosarcoma, Ewing sarcoma of bone,
intermediate or high-grade chondrosarcomas and chordomas and either bone or soft tissue
metastatic CIC-rearranged sarcomas